Effect of Pregabalin on Cardiovascular Responses to Exercise and Postexercise Pain and Fatigue in Fibromyalgia: A Randomized, Double-Blind, Crossover Pilot Study
Table 2
Perception of treatment satisfaction and most commonly reported symptom (Sx) changes in responders and nonresponders during placebo and pregabalin conditions.
(a)
Responders ()
Nonresponders ()
Pregabalin
Placebo
Preg versus Plac
Pregabalin
Placebo
Preg versus Plac
Satisfaction
2.5 ± 0.37
0.3 ± 0.25
<0.001
0.1 ± 0.14
1.6 ± 0.57
0.039
# Sx improved
7.2 ± 1.35
1.3 ± 0.91
<0.001
1.0 ± 0.53
4.3 ± 2.11
0.106
# Sx worse
1.8 ± 0.52
6.4 ± 1.38
0.002
3.7 ± 0.99
1.9 ± 0.63
0.064
(b)
Responders ()
Nonresponders ()
Improved
Worse
Improved
Worse
Placebo condition
≥50%
0
Sleep (7) Physical fatigue (7) Ability to do chores (7) Total energy (6) Muscle pain (6) Mental fog (6)
0
0
25–49%
0
Need for bed rest (5) Headaches (4) PEM (3) Sensitivity to noise (3) Ability to relax (3)
Mental fog (3) Pain (3) Ability to do chores (2) Sleep (2) Need for bed rest (2) Anxiety (2) Depression (2) Back pain (2) Ability to relax (2) Sensitivity to noise (2)
Satisfaction was rated on a 0-to-4 scale, where 0 means “not at all” and 4 means “very much.” # Sx: number of symptoms reported by participants; values are mean ± SE. ≥50% refers to symptoms that were reported in at least 50% of the group. 25–49% refers to symptoms that were reported in 25–49% of the group. PEM: postexertional malaise.